‘Life changing’ treatment approved for severe asthma

Omalizumab (Xolair) is now available for NHS patients as an add-on treatment for severe, persistent allergic asthma in adults, adolescents and children, says NICE.

This follows additional analyses and the submission of a patient access scheme (PAS) by the manufacturer Novartis to the Department of Health which makes the treatment more cost-effective. In previous draft recommendations in November 2012, NICE was unable to recommend the treatment.

 

Latest Issues

AfPP Annual National Conference

University of Warwick
8th - 9th August 2025

IGPP Annual Operating Theatres Show

Manchester, Etihad Stadium
11th September 2025

Clinical Engineering Conference

Stansted Radisson Blu
23rd September 2025

Infection Prevention 2025

Brighton Centre, UK
29th - 30th September 2025

CSC Autumn Meeting

Ramada Plaza, Wrexham
13th October 2025